Chapter I. Pathogenesis

Get Permission
Rev Diabet Stud, 2012, 9(4):224-235 DOI 10.1900/RDS.2012.9.224

Novel Biomarkers in Type 1 Diabetes

Yulan Jin, Jin-Xiong She

Center for Biotechnology and Genomic Medicine and Department of Pathology, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA
Address correspondence to: Jin-Xiong She, Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University,1120 15th Street, Augusta, GA 30912, USA, e-mail:

Manuscript submitted December 16, 2012; resubmitted December 21, 2012; accepted January 8, 2013.

Keywords: type 1 diabetes, biomarker, prediction, pathogenesis, risk, prevention, antibody, INS, CTLA4, PTPN22, IL2RA


Biomarkers are useful tools for research into type 1 diabetes (T1D) for a number of purposes, including elucidation of disease pathogenesis, risk prediction, and therapeutic monitoring. Susceptibility genes and islet autoantibodies are currently the most useful biomarkers for T1D risk prediction. However, these markers do not fully meet the needs of scientists and physicians for several reasons. First, improvement of the specificity and sensitivity is still desirable to achieve better positive predictive values. Second, autoantibodies appear relatively late in the disease process, thus limiting their value in early disease prediction. Third, the currently available biomarkers are not useful for assessing therapeutic outcomes because some are not involved in the disease process (autoantibodies) and others do not change during disease progression (susceptibility genes). Therefore, considerable effort has been devoted to the discovery of novel T1D biomarkers in the last three decades. The advent of high-throughput technologies for genetic, transcriptomic, and proteomic studies has allowed genome-wide examinations of genetic polymorphisms, global gene changes, and protein expression changes in T1D patients and prediabetic subjects. These large-scale studies resulted in the discovery of a large number of susceptibility genes and changes in gene and protein expression. While these studies have provided a number of novel biomarker candidates, their clinical benefits remain to be evaluated in prospective studies, and no new "star biomarker" has been identified until now. Previous studies suggest that significant improvements in study design and analytical methodologies have to be made to identify clinically relevant biomarkers. In this review, we discuss progress, opportunities, challenges, and future directions in the development of T1D biomarkers, mainly by focusing on the genetic, transcriptomic, and proteomic aspects.

Fulltext: HTML , PDF (159KB)

This article has been cited by other articles:

Where, How, and When: Positioning Posttranslational Modification Within Type 1 Diabetes Pathogenesis

McLaughlin RJ, Spindler MP, van Lummel M, Roep BO

Curr Diab Rep 2016. 16(7):63

Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes

Creusot RJ, Battaglia M, Roncarolo MG, Fathman CG

Stem Cells 2016. 34(4):809-819

Metabolomics in childhood diabetes

Frohnert BI, Rewers MJ

Pediatr Diabetes 2016. 17(1):3-14

Risk of type 1 diabetes progression in islet autoantibody-positive children can be further stratified using expression patterns of multiple genes implicated in peripheral blood lymphocyte activation and function

Jin Y, Sharma A, Bai S, Davis C, Liu H, Hopkins D, Barriga K, Rewers M, She JX

Diabetes 2014. 63(7):2506-2515

Impact of anti-glutamic acid decarboxylase-65, anti-insulin and anti-tyrosine phosphatase autoantibodies on disease activity in type 1 diabetes patients

Farhan J, Alghasham A, Zafar U, Meki AR, Rasheed Z

J Diabetes Res Clin Metab 2013. 2:24